Ï㽶ֱ²¥

From the perspective of Joe DePinto, Head of Cell, Gene, and Advanced Therapies with McKesson’s , “It’s an exciting time in the space […] as more and more activity is being seen in health systems, and they’re becoming familiar not only with the clinical mechanisms of cell and gene therapy (CGT) but also with the commercial enablement of CGT in the marketplace.”

Watch the video below for some of Joe’s insights on the promising future of cell and gene therapy in health systems.

Still, he goes on to explain, it’s not the typical product that a health system would utilize on a day-to-day basis, and there are challenges in operationalizing these therapies and programs, making it essential to choose trusted partners who have the experience and expertise to help your health system get these life-changing therapies to patients. “When you think about the science, it’s very complex and really necessitates complex services and solutions so that health systems can have an industrialized standard to deliver cell and gene therapy.”

As part of our Expert Q&A podcast series, Joe sat down with us to answer some of the most pressing questions your health system may be asking about operationalizing cell and gene therapy in health systems, including logistical challenges, financial considerations, patient impact, and more.

Prefer to read the interview? Click here.

To learn more about partnering with McKesson to achieve more, from , or contact us today.